Sector
PharmaceuticalsOpen
₹2,490Prev. Close
₹2,483.8Turnover(Lac.)
₹5,131.15Day's High
₹2,490Day's Low
₹2,441.152 Week's High
₹3,054.852 Week's Low
₹1,901.05Book Value
₹353.13Face Value
₹1Mkt Cap (₹ Cr.)
1,01,568.58P/E
54.38EPS
45.67Divi. Yield
0The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.
Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.
The cumulative demand, including interest charges, is ₹183.11 crore.
The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.
The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 40.06 | 40.06 | 40.06 | 40.06 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 9,583.75 | 7,743.85 | 6,500.39 | 4,694.21 |
Net Worth | 9,623.81 | 7,783.91 | 6,540.45 | 4,734.27 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 12,207.44 | 10,260.44 | 8,749.43 | 7,781.56 | 6,214.43 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,207.44 | 10,260.44 | 8,749.43 | 7,781.56 | 6,214.43 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 553.56 | 296.41 | 140.99 | 210.48 | 182.63 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,699.8 | 93.32 | 3,99,681.22 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,631.5 | 79.74 | 1,76,131.77 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,476.9 | 24.09 | 1,18,622.18 | 1,485.4 | 1.09 | 4,254.47 | 397.44 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,161.1 | 56.17 | 1,07,018.41 | 474 | 1.01 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,248.2 | 19.39 | 1,03,747.84 | 1,200.7 | 0.64 | 5,546.3 | 345.81 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
RAMESH CHAND JUNEJA
Vice Chairman & M.D.
RAJEEV JUNEJA
Whole Time Director & CEO
SHEETAL ARORA
Independent Director
TILOKCHAND PUNAMCHAND OSTWAL
Independent Director
Bharat Anand
Whole-time Director
SATISH KUMAR SHARMA
Independent Director
Vivek Kalra
Independent Director
Vijaya Sampath
Company Sec. & Compli. Officer
Hitesh Kumar Jain
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Mankind Pharma Ltd
Summary
Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to Mankind Pharma Limited and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind tablets and Glimestar tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops and Tobastar Eye Drops. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineralsupplements and anti-acne preparations categories. It entered into the business of animal h
Read More
The Mankind Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2461.8 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma Ltd is ₹101568.58 Cr. as of 29 May ‘25
The PE and PB ratios of Mankind Pharma Ltd is 54.38 and 7.00 as of 29 May ‘25
The 52-week high/low is the highest and lowest price at which a Mankind Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mankind Pharma Ltd is ₹1901.05 and ₹3054.8 as of 29 May ‘25
Mankind Pharma Ltd's CAGR for 5 Years at N/I%, 3 Years at 20.42%, 1 Year at 17.47%, 6 Month at -2.99%, 3 Month at 8.43% and 1 Month at -2.99%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.